Shionogi Science Program invites researchers from selected countries outside Japan into joint studies. The aim is to invite novel, innovative and world-class ideas from researchers to create new pharmaceuticals. The program will adopt projects with budgets of JPY 5-15 million (approximately EUR 37.000-112.000) per year per project for up to 5 years.
Shionogi’s agreement with Denmark on international industry-academia collaboration was established last year and is a cornerstone in the efforts to further accelerate the globalization of the company’s activities.
At that occasion Isao Teshirogi, CEO of Shionogi, explained why Denmark is ideal for a research-driven company like Shionogi:
“Denmark has the ‘Medicon Valley’, one of the famous bio clusters in Europe, and many bio-venture companies as well as academic institutions that actively promote research and development within life science and biotechnology. We are greatly honored to have an opportunity to form cooperative research relationships (…). We expect it to foster international human resources by interacting with researchers with cutting-edge knowledge. Taking advantage of this opportunity, we will accelerate our globalization based on research and development.”
Funding for Danish Pain Research
Earlier this year Aalborg University’s pain research group was the first in Denmark selected to receive funding. Professor and director Lars Arendt-Nielsen at the Center for Sensory-Motor Interaction said:
- “It is a great international recognition and seal of approval of our pain research, and the donation will support us in further intensifying the efforts to understand and measure pain and develop better treatment options for the millions of patients who suffer from chronic pain.”
Regional Project Manager at Invest in Denmark, Theresa Høgenhaug, says:
- “My Japanese colleague in Tokyo and I have cooperated with Shionogi for several years, and they are impressed by the Danish research competences. This is the reason why they initially engaged in public-private cooperation and brought their Science Program to Denmark. The fact that Shionogi have already selected a Danish project and are currently inviting more Danish researchers to apply for next year’s funding shows that Danish research institutions indeed have a lot to offer.
- The administrators of Shionogi Science Program visited Denmark last week and met with researchers from universities and hospitals – they clearly wish to establish close and long term relations with the research community in Denmark and wish to receive a large number of applications from Denmark this year.”
Shionogi Co., Ltd. is an international pharmaceutical company headquartered in Osaka, Japan.
The Science Program is based on the company’s policy to: “Constantly strive to provide medicine of the best possible kind essential for protection of the health of the people”. Under this basic policy Shionogi strives to make a serious effort to have collaboration between industry and academia so that the company can identify novel drug seeds globally and develop them into superior pharmaceuticals.
Read more about Shionogi’s Science program and how to apply.